Clinical Prognostic Factors in Patients With Metastatic Adrenocortical Carcinoma Treated With Second Line Gemcitabine Plus Capecitabine Chemotherapy

Clinical Prognostic Factors in Patients With Metastatic Adrenocortical Carcinoma Treated With Second Line Gemcitabine Plus Capecitabine Chemotherapy

Gemcitabine plus Capecitabine (Gem/Cape) is a frequently adopted second line chemotherapy for metastatic adrenocortical carcinoma (ACC), but only a minority of patients is destined to obtain a clinical benefit. The identification of baseline predictive factors of efficacy is relevant. We retrospecti...

Full description

Bibliographic Details
Main Authors: Salvatore Grisanti, Deborah Cosentini, Marta Laganà, Alessandra Morandi, Barbara Lazzari, Laura Ferrari, Alberto Dalla Volta, Roberta Ambrosini, Vittorio Domenico Ferrari, Sandra Sigala, Alfredo Berruti
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-02-01
Series:Frontiers in Endocrinology
Subjects:
adrenocortical carcinoma
gemcitabine
capecitabine
prognostic factor
chemotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2021.624102/full

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2021.624102/full

Similar Items